STE vs. EW, ALGN, ZBH, SNN, BAX, PODD, HOLX, CAH, LH, and BGNE
Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Edwards Lifesciences (EW), Align Technology (ALGN), Zimmer Biomet (ZBH), Smith & Nephew (SNN), Baxter International (BAX), Insulet (PODD), Hologic (HOLX), Cardinal Health (CAH), Laboratory Co. of America (LH), and BeiGene (BGNE). These companies are all part of the "medical" sector.
STERIS vs.
STERIS (NYSE:STE) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, community ranking, institutional ownership, dividends, analyst recommendations, risk and earnings.
Edwards Lifesciences has higher revenue and earnings than STERIS. Edwards Lifesciences is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.
STERIS presently has a consensus target price of $223.00, indicating a potential upside of 7.74%. Edwards Lifesciences has a consensus target price of $90.00, indicating a potential upside of 7.02%. Given STERIS's stronger consensus rating and higher probable upside, equities research analysts clearly believe STERIS is more favorable than Edwards Lifesciences.
STERIS has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
In the previous week, Edwards Lifesciences had 1 more articles in the media than STERIS. MarketBeat recorded 7 mentions for Edwards Lifesciences and 6 mentions for STERIS. STERIS's average media sentiment score of 0.85 beat Edwards Lifesciences' score of 0.65 indicating that STERIS is being referred to more favorably in the media.
92.4% of STERIS shares are held by institutional investors. Comparatively, 80.4% of Edwards Lifesciences shares are held by institutional investors. 1.0% of STERIS shares are held by insiders. Comparatively, 1.3% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Edwards Lifesciences received 964 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 72.46% of users gave Edwards Lifesciences an outperform vote while only 58.98% of users gave STERIS an outperform vote.
Edwards Lifesciences has a net margin of 27.07% compared to STERIS's net margin of 2.16%. Edwards Lifesciences' return on equity of 25.81% beat STERIS's return on equity.
Summary
Edwards Lifesciences beats STERIS on 13 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
